LIFE-CHANGING INNOVATIONS
About us
Mission
Our mission is to make cutting-edge cell and gene therapies accessible and affordable for those in need. By harnessing the power of AI and advanced biotechnology, we accelerate the development of innovative, life-changing treatments for complex diseases. We are committed to removing barriers in healthcare and ensuring that breakthrough therapies are practically accessible to everyone.
Vision
To lead the next generation of AI-powered healthcare solutions through biotechnology, transforming lives by making advanced therapies affordable and accessible through innovation and excellence.
Core Values
Innovation: We push the boundaries of science and technology to develop groundbreaking therapies.
Accessibility: We focus on making novel healthcare advances available to people globally.
Integrity: We operate with transparency, ethics, and respect in every aspect of our work.
Collaboration: We foster partnerships and work as a team to tackle the world’s toughest healthcare challenges.
Excellence: We strive for high quality in our research and development to improve patient care standards.
Leadership
George Estafanos, MHA, MBBCh (MD), CHIM
(Co-founder & Chief Executive Officer)
Dr. George Estafanos is a physician, entrepreneur, innovator and healthcare strategist with over 25 years of experience in clinical development, health information systems, and artificial intelligence. His career spans public and private sectors, including leadership positions at The Hospital for Sick Children and Horizon Health Network. Before becoming CEO, George served as Vaxx’s Chief Medical Officer and Chief Operating Officer, where he played a key role in advancing the company's AI-driven biotech platform and global partnerships. He holds a medical degree from Ain Shams University, a Master of Health Administration from the University of Regina, and is certified in Health Information Management. As our CEO, George leads Vaxx’s strategic growth, focusing on delivering transformative therapies through innovation, operational excellence, and strong global collaborations.
Suraj Abraham, B.Pharm., M.Eng., Ph.D
(Co-Founder & Chief Technology Officer and Chief Scientific Officer)
Dr. Suraj Abraham is a biotech innovation leader with over 15 years of experience translating cutting-edge science into scalable, platform-driven solutions. A pharmaceutical scientist, bioengineer, and genomic medicine expert, he has led the development of technologies in cell and gene therapy, biologics manufacturing, diagnostics, and AI-powered discovery systems. Dr. Abraham holds a Ph.D. in Cell Biology from the University of Saskatchewan and is an alumnus of BITS Pilani. He is a Chartered Scientist and a member of the Royal Society of Chemistry and the American Association of Pharmaceutical Scientists. He previously held senior R&D and leadership roles at Danaher’s Biotech Group, including Cytiva, Pall Life Sciences, and Precision NanoSystems, where he advanced RNA-LNP nanomedicine for diverse clients and drove technology transfer from early research to CDMO scale-up. He is the author of 22+ publications and multiple patents in next-generation biotech. Currently, Dr. Abraham serves as Head of Platform Development at Vaxx, where he leads the development of CureiTec™, a proprietary AI-native “scientist-in-a-box” platform that accelerates genetic vaccine and cell therapy design. CureiTec™ supports both internal pipelines and early-stage industry collaborations. He also advises as an expert in biotech and healthcare growth strategy at Frost & Sullivan. Known for turning vision into seamless execution, Dr. Abraham brings deep domain expertise, strategic leadership, and a proven track record of delivering platform-based innovations with a global health impact.
Paul Michael Hallelujah, B.Sc., MTS
(Co-Founder & Chief of Staff)
Paul Michael Hallelujah is a multidisciplinary leader with strategic experience spanning life sciences, engineering, medicine, and operations. As Vaxx’s founding CEO, he led the company’s early mission to deliver transformative healthcare solutions and assembled the core team driving Vaxx’s innovation today. A Gold Medalist in Biology from Queen’s University and a top-ranked student in Electrical Engineering, Paul studied medicine for four years at the University of Alberta and Queen’s University before completing his Master of Theological Studies at the University of Toronto. Now serving as Chief of Staff, Paul oversees cross-functional operations, strategic initiatives, and organizational scale-up, supporting the advancement of Vaxx’s AI-powered platform for next-generation therapeutics.
(Co-Founder and Senior Business Advisor)
Dr. Juan Cruz Cuevas, PhD, serves as Senior Business Advisor at Vaxx Research Incorporated, bringing over 20 years of experience in biotechnology, venture capital, and strategic partnerships. At Probius, as Senior Vice President of Marketing and Business Development, Dr. Cuevas led the collaborations and commercialization of Quantum Electrochemical Spectroscopy technology, that makes mathematical representations of biological systems, securing key partnerships in research, Pharmaceutical and biomarker discovery areas. He is also a Venture Parter at SF500, a renowned Argentinean Biotech VC.
Juan has led and contributed to the launch of several products, and commercial strategies with a positive impact on revenue and value creation for shareholders. He earned a bachelor’s degree in Biochemistry from the Universidad Nacional de Cordoba, Argentina, an MS and Ph.D. in Pharmacy and Nutrition from Universitat de Barcelona, Spain, and a master’s in biotechnology management by the IE Business School in Madrid, Spain.
Dr. Cuevas’s proven expertise in biotech commercialization and strategic investment is driving Vaxx’s growth in AI-powered drug discovery and therapeutic innovation.
(Chair, Scientific Advisory Board)
Dr. Michael S. Gottlieb, MD, is a pioneering immunologist renowned for identifying AIDS as a new disease in 1981. As the lead author of the seminal CDC report that marked the official start of the HIV/AIDS epidemic, he first described the syndrome's hallmark CD4+ T-cell deficiency. Dr. Gottlieb has been instrumental in advancing HIV research and treatment, co-founding the American Foundation for AIDS Research (amfAR) and the Elizabeth Glaser Pediatric AIDS Foundation. He served as Rock Hudson's physician and has steadfastly advocated for patients, contributing to early clinical trials of anti-retroviral therapies. After decades of dedicated clinical practice, he retired from APLA Health in 2023 and recently came out of retirement to continue his commitment to patients. Dr. Gottlieb continues to influence global health as a medical advisor to the Global AIDS Interfaith Alliance and the Elizabeth Taylor AIDS Foundation. As a founding advisor of Vaxx, he brings unparalleled expertise in immunology and infectious disease to support developing next-generation HIV cure strategies and immunotherapies.
Channabasavaiah B. Gurumurthy, BVSc, MVSc, PhD, Exec MBA
(Scientific Advisory Board)
Professor C.B. Gurumurthy (Guru) serves as the Head of the Transgenic Facility at the University of Mississippi Medical Center and is a Professor of Genetics. A globally recognized leader in mouse genome engineering, Guru co-developed the groundbreaking Easi-CRISPR and i-GONAD technologies in collaboration with Dr. Masato Ohtsuka, which have revolutionized the creation of genetically engineered mouse models worldwide. His innovations are widely used across academic and industrial laboratories, supporting the annual development of hundreds to thousands of preclinical models. Guru has delivered over 100 invited lectures in the U.S. and presented at major conferences across 12 countries. A recipient of the inaugural Outstanding Genomic Innovator award from the National Human Genome Research Institute, he continues to drive innovation in genome engineering and translational research. Guru is also one of the founding advisors of Vaxx, contributing his expertise to advance next-generation gene and cell therapy development.